nach oben

Journal of Neural Transmission

Erschienen in:

01.02.2013 | Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Is there room for non-dopaminergic treatment in Parkinson disease?

verfasst von: Abraham Lieberman, Narayanan Krishnamurthi

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.

Birkmayer W, Birkmayer G, Lechner H, Riederer P (1983) DL-3,4-threo-DOPS in Parkinson’s disease: effects on orthostatic hypotension and dizziness. J Neural Transm 58(3–4):305–313PubMedCrossRef

Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73(20):1670–1676. doi:10.1212/WNL.0b013e3181c1ded6 PubMedCrossRef

Chung KA, Lobb BM, Nutt JG, Horak FB (2010) Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75(14):1263–1269. doi:10.1212/WNL.0b013e3181f6128c PubMedCrossRef

Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan Y, Xu H, Shaw DE (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci USA 108(32):13118–13123. doi:10.1073/pnas.1104614108 PubMedCrossRef

Kaufmann H (2006) The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl 70:477–484PubMedCrossRef

Kaufmann H (2008) L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auto Res: Off J Clin Auto Res Soc 18(Suppl 1):19–24. doi:10.1007/s10286-007-1002-2 CrossRef

Mathias CJ (2008) L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auto Res: Off J Clin Auto Res Soc 18(Suppl 1):25–29. doi:10.1007/s10286-007-1005-z CrossRef

McFarland K, Price DL, Bonhaus DW (2011) Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease. Behav Pharmacol 22(7):681–692. doi:10.1097/FBP.0b013e32834aff98 PubMedCrossRef

Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 35(4):881–892. doi:10.1038/npp.2009.176 CrossRef

Ogawa N, Yamamoto M, Takayama H (1985) L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson’s disease. J Med 16(5–6):525–534PubMed

Ouattara B, Gasparini F, Morissette M, Gregoire L, Samadi P, Gomez-Mancilla B, Di Paolo T (2010) Effect of l-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 113(3):715–724. doi:10.1111/j.1471-4159.2010.06635.x PubMedCrossRef

Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA (2010) A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39(3):352–361. doi:10.1016/j.nbd.2010.05.001 PubMedCrossRef

Sheffler DJ, Gregory KJ, Rook JM, Conn PJ (2011) Allosteric modulation of metabotropic glutamate receptors. Adv Pharmacol 62:37–77. doi:10.1016/B978-0-12-385952-5.00010-5 PubMedCrossRef

Yarnall A, Rochester L, Burn DJ (2011) The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord: Off J Mov Disord Soc 26(14):2496–2503. doi:10.1002/mds.23932 CrossRef

Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic l-DOPA therapy in advanced Parkinson’s disease. Adv Neurol 69:541–544PubMed

Titel: Is there room for non-dopaminergic treatment in Parkinson disease?
verfasst von: Abraham Lieberman
Narayanan Krishnamurthi
Publikationsdatum: 01.02.2013
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 2/2013
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0946-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Is there room for non-dopaminergic treatment in Parkinson disease?

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations

Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa® therapy

Immunogenicity of botulinum toxins

Association and CpG SNP analysis of HTR4 polymorphisms with suicidal behavior in subjects with schizophrenia

Levodopa increases speed of alternating movements in Parkinson’s disease patients

Controversies in neurology, Vienna, 2012: Steroids in bacterial meningitis: no

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie